Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer.

Abstract	CARD recruited membrane associated protein 3 (CARMA3) overexpression has been found in several human cancers. However, its expression pattern and biological roles in human ovarian cancers are not clear. In this study, we examined the expression pattern of CARMA3 in 101 ovarian cancer specimens. We found that 52 (51.5 %) showed CARMA3 overexpression. CARMA3 overexpression positively correlated with tumor histology and advanced FIGO stage. CARMA3 depletion in ovarian cancer cell lines A2780 and HO8910 inhibited ovarian cancer cell proliferation and blocked cell cycle progression. CARMA3 depletion also sensitized ovarian cancer cells to cisplatin-induced cytotoxicity. In addition, Western blot showed that CARMA3 depletion downregulated cyclin D1, cyclin E, and Bcl-2 levels. In conclusion, our data provides evidence that CARMA3 is overexpressed in ovarian cancers and associated with advanced stage. CARMA3 regulates the ovarian cancer cell proliferation, cell cycle progression, and chemoresistance.
Authors	Chengyao Xie, Yong Han, Lin Fu, Qingchang Li, Xueshan Qiu, Enhua Wang
Journal	Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol) Vol. 35 Issue 8 Pg. 7957-64 (Aug 2014) ISSN: 1423-0380 [Electronic] Netherlands
PMID	24833094 (Publication Type: Journal Article)
Chemical References	Antineoplastic Agents CARD Signaling Adaptor Proteins CARD10 protein, human CCND1 protein, human RNA, Small Interfering Cyclin D1 Cisplatin
Topics	Adult Aged Antineoplastic Agents (pharmacology) CARD Signaling Adaptor Proteins (analysis, antagonists & inhibitors, physiology) Carcinoma, Ovarian Epithelial Cell Cycle Cell Line, Tumor Cisplatin (pharmacology) Cyclin D1 (analysis) Drug Resistance, Neoplasm Female Humans Middle Aged Neoplasm Staging Neoplasms, Glandular and Epithelial (drug therapy, pathology) Ovarian Neoplasms (drug therapy, pathology) Ovary (chemistry) RNA, Small Interfering (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!